2011 was a challenging year for intellectual property (IP) in Brazil, with entrenched anti-IP local interests pitted against the establishment of a contemporary IP-based innovation society.
Important decisions were rendered by national courts on various subjects. In 2011 the first landmark decision recognising and enforcing data-package exclusivity protection for the pharmaceutical industry, limited to a 10-year term for new chemical entities, was made.
Additionally, the discussion about ANVISA’s (the Brazilian Food and Drug Administration) statutory authority to review patentability requirements reached a new, pro-inventor position.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email tech support.
Brazil, BPTO, ANVISA, Schering, Zynga, Germed